Compass (COMP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Compass (COMP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Compass stock price staged a strong comeback on Wednesday after the company boosted its forward guidance. It also jumped as mortgage rates dropped slightly after the latest US inflation data from the United States.
Shares of Compass (COMP) surged nearly 20% Wednesday morning after the largest independent U.S. real estate brokerage boosted its current-quarter and full-year guidance as it increased staffing and controlled costs.
Compass Diversified offers a solid opportunity for income investors, trading at an attractive valuation with a near-5% yield amid recent market volatility. CODI's unique permanent capital structure and long-term ownership approach support sustained growth, driven by strong performance in its branded consumer segment, especially Lugano Diamonds. Despite challenges in the industrial segment, CODI's overall robust financial performance and promising growth outlook make it a compelling pick for income and long-term value investors.
Robert Reffkin, Compass CEO, joins CNBC's 'Squawk on the Street' to discuss what the Fed decision may mean for the housing market.
On Wednesday, Coastal Equity Management released its first ETF, the Coastal Compass 100 ETF (ROPE). ROPE aims to provide large cap upside with the added benefit of dividends and downside security.
Compass Minerals International, Inc. CMP will release its fourth-quarter financial results, after the closing bell, on Monday, Dec. 16.
Compass Group's organic sales expansion for fiscal 2025 might exceed expectations, considering the company's positive growth momentum, its portfolio restructuring efforts, and favorable industry trends. CMPGF's FY 2025 operating margin could surprise on the upside, taking into account the potential margin expansion for its European business and procurement-related efficiency improvement. I am bullish on Compass Group, as I think that positive surprises relating to the company's financial performance in the new fiscal year will be strong re-rating catalysts.
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Compass (COMP) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Compass Therapeutics' CTX-009 shows promise in biliary tract cancer, with a 37.5% response rate in phase 2 trials and a pivotal phase 2/3 readout expected in Q1 2025. Financially, CMPX is stable with $36.8 million in cash and $98.6 million in marketable securities, ensuring a runway through 2025 without major cash concerns. Risks include the non-standard comparator in the pivotal trial and the historically low success rate of novel anti-angiogenic therapies in solid tumors.
Does Compass, Inc. (COMP) have what it takes to be a top stock pick for momentum investors? Let's find out.